# Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573

> **NCT02405065** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 72 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** HM95573

## Key facts

- **NCT ID:** NCT02405065
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-12
- **Primary completion:** 2017-01-18
- **Final completion:** 2018-05-16
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405065, "Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02405065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*